Abbott LaboratoriesABTNYSE
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank54
5Y CAGR-25.7%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
-25.7%/yr
Long-term compound
Percentile
P54
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 18.95% |
| Q3 2025 | 36.15% |
| Q2 2025 | 44.46% |
| Q1 2025 | -50.59% |
| Q4 2024 | 6.03% |
| Q3 2024 | 38.01% |
| Q2 2024 | 91.22% |
| Q1 2024 | -66.26% |
| Q4 2023 | 61.85% |
| Q3 2023 | 56.03% |
| Q2 2023 | 5.25% |
| Q1 2023 | -50.86% |
| Q4 2022 | -16.33% |
| Q3 2022 | 15.35% |
| Q2 2022 | 16.71% |
| Q1 2022 | -32.67% |
| Q4 2021 | 13.55% |
| Q3 2021 | 26.93% |
| Q2 2021 | -19.30% |
| Q1 2021 | -30.57% |
| Q4 2020 | 83.83% |
| Q3 2020 | 56.28% |
| Q2 2020 | 84.90% |
| Q1 2020 | -70.41% |
| Q4 2019 | 24.02% |
| Q3 2019 | 83.77% |
| Q2 2019 | 48.88% |
| Q1 2019 | -59.66% |
| Q4 2018 | -19.15% |
| Q3 2018 | 75.48% |
| Q2 2018 | 12.27% |
| Q1 2018 | -32.44% |
| Q4 2017 | -18.20% |
| Q3 2017 | 48.41% |
| Q2 2017 | 135.37% |
| Q1 2017 | -50.94% |
| Q4 2016 | -3.86% |
| Q3 2016 | 33.88% |
| Q2 2016 | 1077.42% |
| Q1 2016 | -111.23% |